Billing
Requesting Medicare secondary payer conditional payments
Conditional payments are Medicare payments for Medicare covered services for which another insurer is primary payer, made under the condition they are subject to repayment if and when the primary…
Leqembi for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease
Providers may be billing these services incorrectly. Please review this article and pay close attention to the billing loop and segment information detailed within. The NCT number has been added to…
Leqembi for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease
Providers may be billing these services incorrectly. Please review this article and pay close attention to the billing loop and segment information detailed within. The NCT number has been added to…
Reciprocal billing and fee-for-time compensation arrangements (formerly locum tenens arrangements)
The requirements for the submission of claims under reciprocal billing and fee-for-time compensation arrangements are the same for assigned and non-assigned claims. This article shows when these…
Reciprocal billing and fee-for-time compensation arrangements (formerly locum tenens arrangements)
The requirements for the submission of claims under reciprocal billing and fee-for-time compensation arrangements are the same for assigned and non-assigned claims. This article shows when these…
MSP value codes and payer codes
Learn the correct pairing of value codes (VC) and payer codes (PC) to use when billing different types of Medicare secondary payer (MSP) claims.
Conditional payment requests for MSP claims
Providers may file a Medicare secondary payer (MSP) claim and request a conditional payment for a Medicare-covered service when another payer is responsible for payment and is not expected to pay…
340B drug payment policy remedy payment for calendar year (CY) 2018 to CY 2022
View information related to the 340B drug payment policy remedy.
Kisunla for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease
Effective July 2, Medicare will pay for Kisunla for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. Please review this article and pay close attention to the…
Kisunla for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease
Effective July 2, Medicare will pay for Kisunla for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. Please review this article and pay close attention to the…